May. 13 at 4:53 PM
$TLPH Booyah! Let's talk Talphera — T-L-P-H — and I want you to LEAN IN on this one it's a high-wire act with no net! Penny-stock pharma, 1 drug, 1 trial, 1 shot. The drug is Niyad, it's an anticoagulant for the sickest-of-the-sick ICU patients on kidney filtration machines, and either this thing WORKS and you're popping champagne, or it doesn't and you're crying in your cornflakes!
Here's why I'm paying attention: CorMedix — CorMedix! — already wrote them a
$29 million check and has a 60-day EXCLUSIVE window to BUY THEM after trial results. That's a teed-up takeout, people! Trial's 50% enrolled, PMA filing second half of '26.
But — BUT! — Nasdaq's breathing down their neck, they've gotta get back over a buck by September or it's reverse-split city. Dilution everywhere, zero revenue, and every earnings report gets SOLD.
Bottom line? If the trial hits, you've got a double, maybe a triple. If it misses, you're holding a goose egg. House money only. I am NOT your blessing — do your homework!
